We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

64 hedge funds and large institutions have $234M invested in Supernus Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

79% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 14

25% more capital invested

Capital invested by funds: $187M → $234M (+$47M)

12% more funds holding

Funds holding: 57 → 64 (+7)

9% more call options, than puts

Call options by funds: $2.48M | Put options by funds: $2.27M

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
64
Holders Change
+7
Holders Change %
+12.28%
% of All Funds
1.86%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
13
Increased
25
Reduced
14
Closed
6
Calls
$2.48M
Puts
$2.27M
Net Calls
+$200K
Net Calls Change
-$4.83M

Top Buyers

Rank Fund Capital Flow
1
AAP
Ardsley Advisory Partners
Connecticut
+$9.86M
2
OHCM
Orchard Hill Capital Management
New York
+$9.68M
3
Ameriprise
Ameriprise
Minnesota
+$8.27M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.76M
5
MOACM
Mutual of America Capital Management
New York
+$2.72M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$991K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$733K
3
Millennium Management
Millennium Management
New York
-$633K
4
O
OrbiMed
New York
-$415K
5
Deutsche Bank
Deutsche Bank
Germany
-$363K
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
26
Tocqueville Asset Management
New York
$795K – – –
Millennium Management
27
Millennium Management
New York
$684K -$633K -90,513 -50%
CS
28
Credit Suisse
Switzerland
$681K -$62.9K -9,000 -9%
ACP
29
Andalusian Capital Partners
Connecticut
$627K +$581K +83,166 New
Geode Capital Management
30
Geode Capital Management
Massachusetts
$601K +$134K +19,202 +32%
Wellington Management Group
31
Wellington Management Group
Massachusetts
$533K -$12.6K -1,800 -2%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$463K +$27.4K +3,925 +7%
TCIM
33
TIAA CREF Investment Management
New York
$447K -$49.9K -7,140 -11%
BCM
34
Bridgeway Capital Management
Texas
$377K – – –
BIM
35
BlackRock Investment Management
Delaware
$332K +$11.8K +1,694 +4%
U
36
UBS
Switzerland
$260K +$121K +17,278 +100%
Charles Schwab
37
Charles Schwab
California
$240K – – –
MCM
38
McGlinn Capital Management
Pennsylvania
$228K -$79.7K -11,400 -27%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$222K +$19.6K +2,800 +11%
WAM
40
Wolverine Asset Management
Illinois
$187K -$233K -33,300 -57%
DekaBank Deutsche Girozentrale
41
DekaBank Deutsche Girozentrale
Germany
$136K – – –
TA
42
Teachers Advisors
New York
$123K – – –
ProShare Advisors
43
ProShare Advisors
Maryland
$121K -$29.5K -4,220 -21%
State Board of Administration of Florida Retirement System
44
State Board of Administration of Florida Retirement System
Florida
$117K – – –
Citadel Advisors
45
Citadel Advisors
Florida
$113K +$104K +14,929 New
Barclays
46
Barclays
United Kingdom
$98K -$30.6K -4,381 -24%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$97K – – –
NFA
48
Nationwide Fund Advisors
Ohio
$92K +$2.78K +397 +3%
US Bancorp
49
US Bancorp
Minnesota
$83K – – –
Citigroup
50
Citigroup
New York
$83K +$31.5K +4,499 +69%
1
2
3

SUPN Hedge Fund Activity: Q4 2013 in Review

64 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2013, worth a combined $234M — up 25% from $187M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new SUPN positions and 6 closed out — a net gain of 7 holders — while 25 added to existing stakes and 14 trimmed.

The largest buyer was Ardsley Advisory Partners, opening a new position worth an estimated $9.86M. The largest seller was T. Rowe Price Associates, cutting an estimated $991K.

  • 64 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2013, up from 57 in Q3 2013.
  • Funds reported $234M of Supernus Pharmaceuticals stock for Q4 2013, up 25% quarter-over-quarter.
  • 13 funds opened new Supernus Pharmaceuticals positions in Q4 2013 and 6 closed out, a net change of +7 holders.
  • The largest Supernus Pharmaceuticals buyer in Q4 2013 was Ardsley Advisory Partners, an estimated $9.86M added.
  • The largest Supernus Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $991K sold.

Based on aggregated 13F filings for Q4 2013.